Axovant Sciences Announces Pricing of $30 Million Public Offering of Common Shares

Life Science Investing News

Axovant Sciences (Nasdaq:AXON) announced the pricing of its underwritten public offering of 30,000,000 of its common shares at a price to the public of $1.00 per share. As quoted in the press release: Gross proceeds to Axovant from the offering are expected to be approximately $30,000,000 before deducting underwriting discounts and commissions and estimated offering expenses. All of the …

Axovant Sciences (Nasdaq:AXON) announced the pricing of its underwritten public offering of 30,000,000 of its common shares at a price to the public of $1.00 per share.

As quoted in the press release:

Gross proceeds to Axovant from the offering are expected to be approximately $30,000,000 before deducting underwriting discounts and commissions and estimated offering expenses. All of the common shares are being offered by Axovant. In connection with this offering, Axovant has granted the underwriters a 30-day option to purchase up to an additional 4,500,000 of its common shares on the same terms and conditions. The offering is expected to close on December 18, 2018, subject to customary closing conditions.
Jefferies and Guggenheim Securities are acting as joint book-running managers for the offering. JMP Securities is acting as lead manager and H.C. Wainwright & Co. is acting as co-manager for the offering.

Click here to read the full press release.

axovant sciences nasdaq:axon public offering Company News